Zurich Cantonal Bank
GPCR icon

Zurich Cantonal Bank’s Structure Therapeutics GPCR Stock Holding History

Zurich Cantonal Bank’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
385
+173
+82% +$7.65K ﹤0.01% 2479
2026
Q1 		$10.2K Buy
+212
New +$14.5K ﹤0.01% 2483

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Zurich Cantonal Bank's GPCR Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Structure Therapeutics (GPCR) stake by 82% in Q2 2026, buying an estimated $7.65K and bringing the position to 385 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2479.

Zurich Cantonal Bank first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Zurich Cantonal Bank held 385 shares of Structure Therapeutics worth $20.7K as of Q2 2026.
  • Zurich Cantonal Bank bought 173 Structure Therapeutics shares in Q2 2026, an estimated $7.65K.
  • Structure Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2479 holding.
  • Zurich Cantonal Bank first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.